3-methoxytyramine has been researched along with 1-methyl-4-phenylpyridinium in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, Y; Kinemuchi, H; Kisara, K; Matsumura, T; Sakuma, I; Satoh, N; Tadano, T | 1 |
| Cano, J; Machado, A; Merino, M; Vizuete, ML | 1 |
| Caramelli, A; Corsini, GU; Pardini, C; Vaglini, F; Viaggi, C | 1 |
3 other study(ies) available for 3-methoxytyramine and 1-methyl-4-phenylpyridinium
| Article | Year |
|---|---|
Behavioral and biochemical changes following acute administration of MPTP and MPP+.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Desipramine; Dopamine; Homovanillic Acid; Hydroxyindoleacetic Acid; Male; Mice; Motor Activity; Nomifensine; Pyridines; Pyridinium Compounds; Selegiline; Serotonin | 1987 |
The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dopamine Agents; Excitatory Amino Acid Antagonists; Female; Homovanillic Acid; Kynurenic Acid; Microinjections; Neuroprotective Agents; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Kainic Acid; Receptors, N-Methyl-D-Aspartate; Tyrosine 3-Monooxygenase | 1999 |
MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Cytochrome P-450 CYP2E1; Dopamine; Homovanillic Acid; Male; Mice; Mice, Knockout; MPTP Poisoning; Nerve Tissue Proteins; Neurons; Parkinsonian Disorders; Prodrugs; Substantia Nigra; Tyrosine 3-Monooxygenase | 2009 |